Olema Oncology
CA - San FranciscoBiotechnology
Focus: Olema Oncology is a publicly traded San Francisco-based biotech focused on CAR-T brake technology and oncology cell therapy. The company operates at clinical/preclinical stages with modest scale (27 active job openings).
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
33+6 this month
Growing — net +6 jobs in 30d
14 jobs added vs 8 removed. Steady team buildout.
Should You Work at Olema Oncology?
AI assessmentOlema is a high-risk, early-stage bet on emerging CAR-T technology best suited for risk-tolerant scientists and clinicians who can tolerate 3+ years before major readouts.
Why Work Here
- Clinical-heavy hiring (15 of 27 roles) signals active trial execution and advancement toward clinical milestones
- Specialized focus on CAR-T brake technology represents emerging oncology modality with differentiation potential
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Olema Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.